Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

210
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
210
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

131
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
131
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

333
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
333
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

359
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
359
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

362
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
362

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RESPIRIAMO - Italian hospital surveillance for lower respiratory tract infections: a multicenter retrospective cohort study of respiratory syncytial virus-associated hospitalizations in children under 2 years of age.

BMC pediatrics·2026
Same author

Psoriatic arthritis spectrum in children: a multicentre observational study.

Clinical and experimental rheumatology·2026
Same author

"Adnexotropic" lichen striatus: a potential histological mimicker of mycosis fungoides.

Pathologica·2026
Same author

Systemic Sclerosis Without Raynaud Phenomenon in Children: The Fibrotic Subtype.

The Journal of rheumatology·2026
Same author

Trends in emergency department utilization by patients with chronic conditions aged 15 and over in a tertiary-care Italian pediatric emergency department (2010-2022).

Italian journal of pediatrics·2026
Same author

Nailfold videocapillaroscopy in the assessment of juvenile connective tissue diseases.

Clinical and experimental rheumatology·2026
Same journal

Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives.

Current rheumatology reports·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K

Treatment in Juvenile Scleroderma.

Francesco Zulian1, Francesca Tirelli2

  • 1Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy. francescozulian58@gmail.com.

Current Rheumatology Reports
|June 28, 2020
PubMed
Summary
This summary is machine-generated.

Juvenile scleroderma treatment is challenging. Recent European guidelines standardize care, confirming methotrexate and exploring mycophenolate mofetil and biologics for severe cases.

Keywords:
Antirheumatic drugsBiologicsImmunosuppressive agentsJuvenile-onset sclerodermaScleroderma, localizedScleroderma, systemic

More Related Videos

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

8.1K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.2K

Related Experiment Videos

Last Updated: Dec 17, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.3K
Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia
12:25

Second Harmonic Generation Signals in Rabbit Sclera As a Tool for Evaluation of Therapeutic Tissue Cross-linking TXL for Myopia

Published on: January 6, 2018

8.1K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.2K

Area of Science:

  • Pediatric Rheumatology
  • Dermatology
  • Autoimmune Diseases

Background:

  • Juvenile scleroderma (JS) treatment is complex due to limited understanding of its pathogenesis.
  • Current treatment strategies for JS often rely on adult data owing to the condition's rarity.

Purpose of the Study:

  • To review the latest evidence and recommendations for treating juvenile scleroderma.
  • To highlight standardized approaches and emerging therapies for localized and systemic forms of JS.

Main Methods:

  • Review of recent European guidelines (SHARE) for pediatric rheumatology.
  • Analysis of the impact of the Juvenile Systemic Sclerosis (J4S) severity score on patient assessment.
  • Synthesis of current treatment practices based on adult experience and emerging research.

Main Results:

  • Systemic treatment for localized scleroderma is indicated for high-disability risk cases (e.g., generalized morphea).
  • The J4S score aids in standardized assessment and tailored therapy for juvenile systemic sclerosis.
  • Methotrexate remains a cornerstone, with mycophenolate mofetil and biologics showing promise for refractory cases.

Conclusions:

  • Recent recommendations provide a standardized framework for juvenile scleroderma management.
  • Established treatments like methotrexate are confirmed, alongside novel options for severe or treatment-resistant disease.
  • Further research into effective experimental treatments is crucial for improving outcomes in juvenile scleroderma.